Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients (COMPETE)

Clinical Trial ID NCT02532400

Rank	Title	Journal	Year	PubWeight™‹?›
1	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.	Lancet	2014	9.66
2	Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.	J Clin Oncol	2012	8.74
3	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.	N Engl J Med	2014	6.76
4	Adjuvant ovarian suppression in premenopausal breast cancer.	N Engl J Med	2014	5.18
5	Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.	J Natl Cancer Inst	2005	4.48
6	-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.	Ann Oncol	2015	4.31
7	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	J Clin Oncol	2011	2.71
8	Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.	Lancet Oncol	2012	2.25
9	Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.	Cancer	2007	1.53